Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00427583
Recruitment Status :
(stopped due to slow recruitment and no effect)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients ≥18 years of age
Histologically documented diagnosis of malignant MPNST
Unresectable local MPNST or metastatic MPNST and therefore incurable with any conventional multimodality approach Life expectancy of at least 6 months.
Patient has received any other investigational agents within 28 days of first day of study drug dosing.
Chemotherapy and or radiotherapy in between the last 6 weeks before study entry, surgery in between the last 14 days before study entry.
Female patients who are pregnant or breast feeding or women of child bearing potential who are not using a highly effective method of birth control.
Known CNS metastases
Other protocol-defined inclusion/exclusion criteria may apply.
Nerve Sheath Neoplasms
Neoplasms, Nerve Tissue
Neoplasms by Histologic Type
Peripheral Nervous System Neoplasms
Nervous System Neoplasms
Nervous System Diseases
Peripheral Nervous System Diseases
Neoplasms, Fibrous Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Protein Kinase Inhibitors
Molecular Mechanisms of Pharmacological Action